Τμήμα Ιατρικής
Πανεπιστημίου Πατρών
Προσωπικό - Κυπραίος Κ.

Κυπραίος Κυριάκος, Καθηγητής

Τομέας: Βασικών Ιατρικών Επιστημών ΙΙ

Κλινική/Εργαστήριο: Εργαστήριο Γενικής Φαρμακολογίας

Γνωστικό Αντικείμενο: ΦΑΡΜΑΚΟΛΟΓΙΑ

Ερευνητικοί Τομείς Ενδιαφέροντος: ΦΑΡΜΑΚΟΛΟΓΙΑ ΤΟΥ ΜΕΤΑΒΟΛΙΚΟΥ ΣΥΝΔΡΟΜΟΥ

ΠΑΝΕΠΙΣΤΗΜΙΟ ΠΑΤΡΩΝ, ΤΜΗΜΑ ΙΑΤΡΙΚΗΣ, ΠΑΝΕΠΙΣΤΗΜΙΟΥΠΟΛΙΣ, ΡΙΟ ΑΧΑΪΑΣ, ΤΚ. 26500, ΕΛΛΑΣ ΚΤΙΡΙΟ ΠΡΟΚΛΙΝΙΚΩΝ ΛΕΙΤΟΥΡΓΕΙΩΝ, 3ος ΟΡΟΦΟΣ

- kkypreos@med.upatras.gr

Ανάκτηση Βιογραφικού Σημειώματος

Περίληψη Βιογραφικού Σημειώματος

Our team is composed of undergraduate and graduate students, medical students, basic scientists, and medical doctors, all working on the pharmacology of metabolic syndrome. In particular our activities focus on the identification of lead compounds for the treatment of the metabolic syndrome, with particular emphasis on dyslipidemia, obesity, and diabetes. Using unique animal models and advanced molecular pharmacology approaches coupled with modern gene transfer methodologies, we aim at unraveling the molecular basis of conditions associated with the syndrome and at identifying select genes with important roles in the pathogenesis and treatment of these pathologies. Ultimate goal of our studies is the identification of novel lead compounds and biological drugs for the individualization of therapies. To this effect, scientists of the team combine expertise from numerous biomedical disciplines. Our research projects are oriented towards the development of personalized treatments tailored to the individual patient needs by use of the genetic and other information that we collect from our basic science studies. We expect that our findings will foster the development of molecular diagnostic assays to assess patient's risk for a number of medical conditions and tailor individual preventative treatments (including nutritional and lifestyle interventions) or propose individual pharmaceutical inteventions (classical chemical compounds or biological drugs via gene therapy) based on the genetic profile of each individual.For a complete description of our research activities please refer to pubmed. Our laboratory is located at: University of Patras School of Health Sciences Department of Medicine Pharmacology Laboratory 3rd floor of Preclinical Research Building Panepistimioupolis Rio-Achaias, TK. 26500 Greece TEL: +302610997939 EMAIL: kypraioslab@gmail.com

Προπτυχιακά Μαθήματα

Μεταπτυχιακά Μαθήματα

  • Ερευνητικά Θέματα (ΠΜΣ - Βασικών Ιατρικών Επιστημών)
  • Σεμινάρια Προσκεκλημένων Ομιλητών Ι (ΠΜΣ - Βασικών Ιατρικών Επιστημών)
  • Μεθοδολογία της έρευνας στις Βασικές Ιατρικές Επιστήμες II (ΠΜΣ - Βασικών Ιατρικών Επιστημών)
  • Σεμινάρια Προσκεκλημένων Ομιλητών ΙΙ (ΠΜΣ - Βασικών Ιατρικών Επιστημών)
  • Φαρμακοκινητική – Τοξικολογία (ΠΜΣ - Βασικών Ιατρικών Επιστημών)
  • Σεμινάρια Προσκεκλημένων Ομιλητών ΙΙΙ (ΠΜΣ - Βασικών Ιατρικών Επιστημών)
  • Σεμινάρια Φοιτητών Ι (ΠΜΣ - Βασικών Ιατρικών Επιστημών)
  • Σεμινάρια προσκεκλημένων ομιλητών ΙV (ΠΜΣ - Βασικών Ιατρικών Επιστημών)
  • Σεμινάρια Φοιτητών ΙΙ (ΠΜΣ - Βασικών Ιατρικών Επιστημών)
  • Παρουσίαση Αποτελεσμάτων (ΠΜΣ - Βασικών Ιατρικών Επιστημών)

Επιλεγμένες Δημοσιεύσεις

1. Kyriakos E. Kypreos, Spyridon Gkizas, Loukianos S. Rallidis, Iordanis Karagiannides (2013) HDL particle functionality as a primary pharmacological target for HDL-based therapies. Biochemical Pharmacology, 10.1016/j.bcp.2013.03.004

 

2. Angeliki Lampropoulou, Vassilis I. Zannis, Kyriakos E. Kypreos (2012) Pharmacodynamic and pharmacokinetic analysis of apoE4 [L261A, W264A, F265A, L268A, V269A], a recombinant apolipoprotein E variant with improved biological properties. Biochemical Pharmacology, 84(11):1451-8. doi: 10.1016/j.bcp.2012.09.006. Epub 2012 Sep 14.

 

3. Irene-Eva Triantaphyllidou, Eleni Karavia, Eleni Kalyvioti, Ioannis Lilis, Kyriakos E. Kypreos, and Dionysios J. Papachristou (2012) Perturbations in ithe HDL metabolic pathway predispose to the development of osteorthritis in mice follwoing long-term exposure to westen-type diet. Osteoarthritis Cartilage, (Nov 11. pii: S1063-4584(12)01016-3. doi: 10.1016/j.joca.2012.11.003).

 

4. Eleni A. Karavia, Dionysios J. Papachristou, Kassiani Liopeta, Irene-Eva Triantafyllidou, Odyssefs Dimitrakopoulos, and Kyriakos E. Kypreos (2012) Apolipoprotein A-I modulates Processes Associated with Diet-Induced Nonalcoholic Fatty Liver Disease in Mice, Mol. Med (Sep 7;18(9):901-12. doi 10.2119/molmed.2012.00113.).

 

5. Kyriakos E. Kypreos (2012) HDL Quality in Atherosclerosis: can ratios between apolipoproteins of HDL be used effectively to indicate risk of premature myocardial infarction? Clin. Lipidol. 7:127-29. (Invited Editorial).

 

6. Eleni Karavia, Dionysios J. Papachristou, Ioanna Kotsikogianni, Irene-Eva Triantafyllidou, and Kyriakos E. Kypreos (2012) Lecithin:cholesterol acyltransferase modulates the severity of diet-induced nonalcoholic fatty liver disease in mice. J. Nutr. Biochem. DOI: 10.1016/j.jnutbio.2012.02.007.

 

7. Anthula E. Kavo, Loukianos Rallidis, George C. Sakellaropoulos, Stefan Lehr, Sonja Hartwig, Juergen Eckel, Polixeni Mpozatzi, Panagiota Tsikrika, and Kyriakos E. Kypreos (2012) Qualitative characteristics of HDL particles in young asymptomatic patients of an acute myocardial infarction. Atherosclerosis, 220:257-64.

 

8. Eleni Karavia, Dionysios J. Papachristou, Ioanna Kotsikogianni and Kyriakos E. Kypreos (2011) Deficiency in Apolipoprotein E has a Protective effect on Diet-Induced Nonalcoholic Fatty Liver Disease in Mice. FEBS J, 278:3119-29. [PUBMED]

 

9. Peristera A. Petropoulou, Donald L. Gantz, Yanan Wang, Patrick C.N. Rensen, and Kyriakos E. Kypreos (2011). The aminoterminal 1-185 domain of human apolipoprotein E suffices for the de novo biogenesis of apoE-containing HDL. Atherosclerosis, 219:116-23.

 

10. Abdul Traish and Kyriakos E. Kypreos (2010) Testosterone and Cardiovascular Disease: An Old Idea with Modern Clinical Implications, Atherosclerosis, 214:244-8.

 

11. Eirini M. Tsompanidi, Maria S. Brinkmeyer, Elisavet H. Fotiadou, Smaragda M. Giakoumi, and Kyriakos E. Kypreos (2010) HDL biogenesis and functions: Role of HDL quality and quantity in atherosclerosis. Atherosclerosis, 208: 3-9.

 

12. Abdulmaged M. Traish, Rami Abdou, and Kyriakos E. Kypreos (2009) Androgen deficiency and atherosclerosis: The lipid link. Vascul Pharmacol. 51: 303-13.

Επίβλεψη Διδακτορικών Διατριβών